Feb 26, 2026 09:00AM
Jan 23, 2026 12:56PM
Dec 21, 2025 04:00AM
Dec 8, 2025 08:00AM
Dec 8, 2025 08:00AM
Oct 27, 2025 12:29AM
Oct 26, 2025 11:30AM Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shel
Sep 3, 2025 06:20AM
Aug 12, 2025 04:01PM
Jun 11, 2025 01:00PM
Jun 11, 2025 09:02AM
Jun 11, 2025 09:00AM
May 13, 2025 04:01PM
Apr 14, 2025 08:01AM Fate Therapeutics (FATE) Receives RMAT Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus
Apr 14, 2025 08:00AM
Mar 6, 2025 05:19AM
Mar 5, 2025 04:01PM
Jan 2, 2025 04:00PM
Nov 12, 2024 04:01PM
Aug 13, 2024 04:05PM
May 9, 2024 04:01PM Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
May 9, 2024 08:38AM
May 9, 2024 08:30AM
Nov 8, 2023 04:01PM
Aug 8, 2023 04:01PM
May 3, 2023 04:01PM
Mar 12, 2023 09:00PM
Feb 28, 2023 04:01PM Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Feb 28, 2023 04:01PM
Feb 2, 2023 09:47AM
Feb 2, 2023 09:46AM
Jan 18, 2023 09:00PM
Jan 6, 2023 08:28AM
Jan 5, 2023 05:00PM
Jan 5, 2023 05:00PM Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
Jan 5, 2023 05:00PM
Dec 13, 2022 08:00AM
Dec 13, 2022 08:00AM
Dec 10, 2022 10:00AM
Dec 10, 2022 10:00AM
Nov 7, 2022 08:11AM
Nov 7, 2022 08:00AM Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
Nov 7, 2022 08:00AM
Nov 3, 2022 04:01PM
Nov 3, 2022 04:01PM
Aug 3, 2022 04:01PM
Aug 3, 2022 04:01PM
May 5, 2022 08:39AM
May 4, 2022 04:01PM Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress
May 4, 2022 04:01PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All